Intervention
tucatinib
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 7 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
7 shownTucatinib Continuation StudyNCT07768358 · 2026-11-06
NOT_YET_RECRUITINGA Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsNCT06157892 · 2024-05-20
ACTIVE_NOT_RECRUITINGA Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive CancersNCT05091528 · 2022-02-08
TERMINATEDBasket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 AlterationsNCT04579380 · 2021-01-11
ACTIVE_NOT_RECRUITINGA Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast CancerNCT04539938 · 2020-12-01
COMPLETEDA Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerNCT03975647 · 2019-10-02
ACTIVE_NOT_RECRUITINGA Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast CancerNCT02614794 · 2016-01-28
COMPLETEDCommon conditions
HER2-positive Breast Cancer3Biliary Tract Neoplasms2HER2 Positive Breast Cancer2Advanced Breast Cancer1Advanced Gastric Cancer1Advanced Non-Small Cell Lung Cancer1Breast Neoplasms1Carcinoma, Non-Small-Cell Lung1Cervical Cancer1Colorectal Cancer1Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)1Gastroesophageal Junction Adenocarcinoma1HER2 Low Breast Neoplasms1HER2 Mutations Breast Neoplasms1HER2 Positive Breast Neoplasms1HER2-expressing Non-small Cell Lung Cancer1HER2-positive Colorectal Cancer1HER2-positive Gastric Cancer1Metastatic Breast Cancer1Metastatic Gastric Cancer1Stomach Neoplasms1Triple Negative Breast Neoplasms1Urologic Neoplasms1Urothelial Cancer1Uterine Cervical Neoplasms1
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING3
COMPLETED2
NOT_YET_RECRUITING1
TERMINATED1
Phase mix
PHASE25
PHASE11
PHASE31
PHASE41
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.